Cardiovascular safety of sublingual apomorphine in patients on stable doses of oral antihypertensive agents and nitrates

被引:18
作者
Fagan, TC
Buttler, S
Marbury, T
Taylor, A
Edmonds, A
机构
[1] Univ Arizona, Coll Med, Dept Med, Tucson, AZ USA
[2] Univ Arizona, Coll Med, Dept Pharmacol, Tucson, AZ 85724 USA
[3] TAP Pharmaceut Prod Inc, Lake Forest, IL USA
[4] Orlando Clin Res Ctr, Orlando, FL USA
[5] Baylor Coll Med, Dept Med, Houston, TX 77030 USA
[6] Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA
关键词
D O I
10.1016/S0002-9149(01)01847-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Sublingual (SL) apomorphine (2 to 6 mg) has been shown to be effective for treatment of male erectile dysfunction. Many patients with erectile dysfunction are also being treated for systemic hypertension and/or cardiovascular disease. In a double-blind, randomized, placebo-controlled, crossover trial, SL apomorphine 5 mg and placebo were administered on alternate days to 162 men who were on long-term therapy (greater than or equal to4 weeks) with angiotensin-converting enzyme inhibitors, beta blockers, diuretics, calcium channel blockers, alpha (1) blockers, or short- or long-acting nitrates. Blood pressure and heart rate were measured before and after dosing; cardiac rhythm was recorded by 4-hour Halter monitoring. The only potentially clinically significant interactions between SL apomorphine and the antihypertensive agents or short-acting nitrates were greater orthostatic decreases in systolic blood pressure in the alpha -blocker and calcium channel blocker groups (- 10 and -6 mm Hg vs placebo, respectively). Administration of SL apomorphine after dosing with long-acting nitrates resulted in significant decreases in blood pressure when patients were standing (mean systolic change, -5 to -9 mm Hg 30 to 60 minutes postdose, p <0.05; mean diastolic change, -3 to -4 mm Hg 50 to 60 minutes postdose, p <0.05). The most common adverse events with SL apomorphine were dizziness, nausea, and headache. Syncope occurred in 1 patient in the beta -blocker group; symptomatic hypotension occurred in 2 patients each in the short- and long-acting nitrate groups. Thus, in patients receiving common antihypertensive agents and short-acting nitrates, as well as in most patients receiving long-acting nitrates, SL apomorphine at higher than recommended doses produced no clinically significant changes in heart rate or blood pressure greater than changes seen with SL apomorphine alone. (C) 2001 by Excerpta Medica, Inc.
引用
收藏
页码:760 / 766
页数:7
相关论文
共 7 条
[1]   Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction [J].
Dula, E ;
Keating, W ;
Siami, PF ;
Edmonds, A ;
O'Neil, J ;
Buttler, S .
UROLOGY, 2000, 56 (01) :130-135
[2]   RECOVERY OF ERECTILE FUNCTION BY THE ORAL-ADMINISTRATION OF APOMORPHINE [J].
HEATON, JPW ;
MORALES, A ;
ADAMS, MA ;
JOHNSTON, B ;
ELRASHIDY, R .
UROLOGY, 1995, 45 (02) :200-206
[3]   THE CHARACTERIZATION OF A BIOASSAY OF ERECTILE FUNCTION IN A RAT MODEL [J].
HEATON, JPW ;
VARRIN, SJ ;
MORALES, A .
JOURNAL OF UROLOGY, 1991, 145 (05) :1099-1102
[4]   Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy [J].
Kloner, RA ;
Brown, M ;
Prisant, LM ;
Collins, M .
AMERICAN JOURNAL OF HYPERTENSION, 2001, 14 (01) :70-73
[5]  
MARRIOTT HJL, 1983, PRACTICAL ELECTROCAR, P349
[6]   Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication [J].
Zusman, RM ;
Prisant, LM ;
Brown, MJ .
JOURNAL OF HYPERTENSION, 2000, 18 (12) :1865-1869
[7]  
2001, PHYSICIANS DESK REFE, P2534